This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Diasio RB. An evolving role for oral fluoropyrimidine drugs. J Clin Oncol 2002; 20: 894–896.DiasioRBAn evolving role for oral fluoropyrimidine drugs20022089489610.1200/JCO.2002.20.4.894Search in Google Scholar
Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291–297.SchullerJCassidyJDumontEPreferential activation of capecitabine in tumor following oral administration in colorectal cancer patients20004529129710.1007/s002800050043Search in Google Scholar
Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–1281.MiwaMUraMNishidaMDesign of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue1998341274128110.1016/S0959-8049(98)00058-6Search in Google Scholar
Twelves C. Vision of the future: Capecitabine. Oncologist 2001; 6 (Suppl 4): 35–39.TwelvesCVision of the future: Capecitabine20016Suppl 4353910.1634/theoncologist.6-suppl_4-35Search in Google Scholar
Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–575.CassidyJTwelvesCVan CutsemEFirst-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin20021356657510.1093/annonc/mdf089Search in Google Scholar
Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: a large Phase II study. Proc Am Soc Clin Oncol 2002; 21:62FumoleauPLargillierRTrillet-LenoirVCapecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: a large Phase II study20022162Search in Google Scholar
O’Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized, open label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247–1254.O’ShaughnessyJBlumJMoiseyenkoVRandomized, open label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer2001121247125410.1023/A:1012281104865Search in Google Scholar
O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812–2823.O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: Phase III trial results2002202812282310.1200/JCO.2002.09.002Search in Google Scholar
Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–1768.BlumJLDierasVLo RussoPMMulticenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients2001921759176810.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-ASearch in Google Scholar
Taguchi T, Nakayama T, Masuda N, Yoshidome K, et al. Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010; 56(2):166–170.TaguchiTNakayamaTMasudaNYoshidomeKStudy of low-dose capecitabine monotherapy for metastatic breast cancer201056216617010.1159/000313531Search in Google Scholar
Ambros T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Aruna M, et al. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat 2014;146(1):7–14.AmbrosTZeichnerSBZaravinosJMonteroAJAhnEArunaMA retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer2014146171410.1007/s10549-014-3003-xSearch in Google Scholar
Bertelsen C, Ji L, Garcia A, Russell C, et al. Efficacy of Very-Low-Dose Capecitabine in Metastatic breast Cancer. Am J Hematol 2014; 11(2):20–30BertelsenCJiLGarciaARussellCEfficacy of Very-Low-Dose Capecitabine in Metastatic breast Cancer20141122030Search in Google Scholar
Nishijima T, Suzuki M, Hyman B. A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2016 April ; 156(2): 227–236.NishijimaTSuzukiMHymanBA comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis2016April156222723610.1007/s10549-016-3756-5498883126988358Search in Google Scholar
Rudek M, Connolly R, Hoskins J, Mayer E, et al. Fixed dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat 2013 May; 139(1): 135–143.RudekMConnollyRHoskinsJMayerEFixed dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer2013May139113514310.1007/s10549-013-2516-z367330023588952Search in Google Scholar
Koedoot CG, De Haes JC, Heisterkamp SH, Bakker PJ, et al. Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 2002;20(17):3658–3664.KoedootCGDe HaesJCHeisterkampSHBakkerPJPalliative chemotherapy or watchful waiting? A vignettes study among oncologists200220173658366410.1200/JCO.2002.12.01212202667Search in Google Scholar
Rossi D, Alessandroni P, Catalano V et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer 2007; 7(11): 857–860.RossiDAlessandroniPCatalanoVSafety profile and activity of lower capecitabine dose in patients with metastatic breast cancer200771185786010.3816/CBC.2007.n.05018269775Search in Google Scholar
Kawaguchi T, Iwase S, Takeuchi H, et al. Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J 2009;2:9081.KawaguchiTIwaseSTakeuchiHChemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report20092908110.1186/1757-1626-2-9081280387820062718Search in Google Scholar
Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17(2): 485–493.BlumJLJonesSEBuzdarAUMulticenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer199917248549310.1200/JCO.1999.17.2.48510080589Search in Google Scholar
Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18(6): 1337–1345.Van CutsemEFindlayMOsterwalderBCapecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study20001861337134510.1200/JCO.2000.18.6.133710715306Search in Google Scholar
Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26(13): 2118–2123.HallerDGCassidyJClarkeSJPotential regional differences for the tolerability profiles of fluoropyrimidines200826132118212310.1200/JCO.2007.15.209018445840Search in Google Scholar
Sezgin C, Kurt E, Evrensel T et al. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. South Med J 2007; 100(1): 27–32.SezginCKurtEEvrenselTEfficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome20071001273210.1097/01.smj.0000252968.87824.1917269522Search in Google Scholar
Hennessy B, Gauthier A, Michaud L, Hortobagyi G, et al Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16: 1289–1296.HennessyBGauthierAMichaudLHortobagyiGLower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature2005161289129610.1093/annonc/mdi25315890665Search in Google Scholar
Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–575.CassidyJTwelvesCVan CutsemEFirst-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin20021356657510.1093/annonc/mdf08912056707Search in Google Scholar
Zielinski C, Gralow J, Martin M. Optimizing the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann Oncol 2010; 21: 2145–2152.ZielinskiCGralowJMartinMOptimizing the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?2010212145215210.1093/annonc/mdq06920332132Search in Google Scholar
Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine (Xeloda) v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–2292.HoffPMAnsariRBatistGComparison of oral capecitabine (Xeloda) v intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study2001192282229210.1200/JCO.2001.19.8.228211304782Search in Google Scholar
Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367–1372.TalbotDCMoiseyenkoVVan BelleSRandomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines2002861367137210.1038/sj.bjc.6600261237538411986765Search in Google Scholar
Harbeck N, Saupe S, Jäger E, Schmidt M, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: Results of the PELICAN study. Breast Cancer Res Treat 2017;161(1):63–72.HarbeckNSaupeSJägerESchmidtMA randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: Results of the PELICAN study20171611637210.1007/s10549-016-4033-3522291527798749Search in Google Scholar
Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29(10):1252–1260.RobertNJDierasVGlaspyJBrufskyAMBondarenkoILipatovONRIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer201129101252126010.1200/JCO.2010.28.098221383283Search in Google Scholar
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011; 29(34):4498–4504.StocklerMRHarveyVJFrancisPAByrneMJAcklandSPFitzharrisBCapecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer201129344498450410.1200/JCO.2010.33.910122025143Search in Google Scholar
Debled M, Madranges N, Trainaud A, et al. First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? Oncology 2009; 77: 318–327.DebledMMadrangesNTrainaudAFirst-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?20097731832710.1159/00026090419940523Search in Google Scholar
Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23(10): 2155–2161.BajettaEProcopioGCelioLSafety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women200523102155216110.1200/JCO.2005.02.16715710946Search in Google Scholar